News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
GEMMABio Launches Rare Therapeutics. to Develop and Deliver Gene Therapies for Rare Diseases
Rare Therapeutics is a clinical-stage company focused on developing accessible and sustainable gene therapies for ultra-orphan diseases.
MavriX Bio Receives FDA Fast Track Designation for Angelman Syndrome Treatment
MavriX is a Penn startup company based on technology developed by James Wilson, MD, PhD.
Verismo Therapeutics Announces Clinical Trial Partnership with Miltenyi Biotec
Verismo successfully manufactured its first clinical cell product using viral vector supplied by Miltenyi Bioindustry.
Dispatch Bio Named a 2025 Startup Company to Watch by Endpoints News
The company was recognized for bringing ‘universality’ to cell therapies for solid tumors.
BlueWhale Bio Reaches Major Cell Therapy Clinical Milestone
The company aims to streamline the manufacturing process for huCART19-IL18 cells in the treatment of hematologic cancers.
Penn Ranked as Inc. and Fast Company’s #2 “Ignition School” for the Second Year in a Row
Rankings are determined based on the number of alumni ventures and money raised, startups created, patents awarded annually, and research awards.
FDA Approval of New Treatment for Glioma Based on Penn IP
This newly approved therapy is based on technology jointly owned by Penn, Wayne State University and Penn State University.
Philly Tech Week’s Pennovation Zone
Pennovation Works hosted "The Pennovation Zone,"an interactive area that featured Pennovation Works members, tenants and Accelerator alumni shared insights on their current projects.
5 Penn Teams Accepted into NSF I-Corps Mid Atlantic Hub’s Biotech Cohort
These teams will get hands-on customer discovery, value-prop testing and mentor guidance to bring their innovation to market.
Smart Dosimetry System (SDS) Accepted into National NSF I-Corps Program
The program awards $50,000 to advance groundbreaking technologies through intensive customer discovery and market validation.